Comparative Pharmacology
Head-to-head clinical analysis: ARNUITY ELLIPTA versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARNUITY ELLIPTA versus AZMACORT.
ARNUITY ELLIPTA vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. This reduces airway inflammation and hyperresponsiveness.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
1 inhalation (100 mcg fluticasone furoate) once daily via oral inhalation, with or without a spacer.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
The terminal elimination half-life of fluticasone furoate is approximately 24 hours. This long half-life supports once-daily dosing and contributes to sustained anti-inflammatory effects in the lungs.
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Fluticasone furoate is eliminated primarily via hepatic metabolism and subsequent biliary excretion. Following oral administration, approximately 90% of the dose is excreted in feces as metabolites, with less than 1% excreted unchanged in urine. Renal excretion of unchanged drug is negligible.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid